ZIOPHARM Oncology(NASDAQ:ZIOP) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $1.70M. Analysts estimated a revenue of $1.52M. Earnings per share were $-0.10. Analysts had estimated an EPS of $-0.11.
In a different note, Raymond James said it Initiates Coverage on ZIOPHARM Oncology, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Market Perform’ by the firm.
ZIOPHARM Oncology (ZIOP) made into the market gainers list on Wednesdays trading session with the shares advancing 1.55% or 0.09 points. Due to strong positive momentum, the stock ended at $5.89, which is also near the day’s high of $6.025. The stock began the session at $5.78 and the volume stood at 17,13,333 shares. The 52-week high of the shares is $14.93 and the 52 week low is $4.45. The company has a current market capitalization of $776 M and it has 13,17,32,423 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at $12.84 per share price.Also, On Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at $10.12 per share price.On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at $9.67 per share price, according to the Form-4 filing with the securities and exchange commission.
ZIOPHARM Oncology Inc. is a biopharmaceutical company. The Company is engaged in the acquisition development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company’s clinical stage product candidate Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12 or IL-12 a potent naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex for the treatment of metastatic melanoma and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).